In summary, patients with any histologic type (adenocarcinoma or squamous cell carcinoma) and any PD-L1 CPS expression may benefit and are good candidates for combination chemo-IO in first-line treatment. This evidence concerns the gene CD274 and squamous cell carcinoma.